Triple
T4850507
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Heptares Therapeutics |
E108401
|
entity |
| Predicate | collaboratesWith |
P37
|
FINISHED |
| Object | Kymab |
E422485
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Kymab | Statement: [Heptares Therapeutics, collaboratesWith, Kymab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Kymab Context triple: [Heptares Therapeutics, collaboratesWith, Kymab]
-
A.
Kymab
chosen
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
B.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
Cambridge Antibody Technology
Cambridge Antibody Technology was a pioneering UK biotechnology company best known for developing human monoclonal antibody technologies that led to blockbuster therapeutic drugs.
-
E.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69bd440a89548190a5f14ba6da6b97dc |
completed | March 20, 2026, 12:56 p.m. |
| NER | Named-entity recognition | batch_69bd6d1e5cf08190bd6b6a524748f170 |
completed | March 20, 2026, 3:51 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69be5cdefda8819095fbc04446bf32f5 |
completed | March 21, 2026, 8:54 a.m. |
Created at: March 20, 2026, 1:25 p.m.